培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的疗效分析.docVIP

培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的疗效分析 　　摘要：目的 探讨培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的疗效。方法 收集2012年3月～2014年6月我院诊断为晚期非鳞非小细胞肺癌的患者，随机分为两组：50例研究组和50例对照组。研究组接受培美曲塞联合顺铂治疗，对照组接受吉西他滨联合顺铂治疗。结果 ①研究组和对照组平均化疗周期、临床分期结果比较无差异（P0.05）。②研究组和对照组化疗治疗有效率分别为36%、22%，结果比较有差异（P0.05）。③研究组和对照组血小板减少、谷丙转氨酶升高不良反应结果比较有差异（P0.05）。结论 本次研究认为培美曲塞联合顺铂治疗晚期非鳞非小细胞肺癌疗效肯定，安全性好。 　　关键词：培美曲塞；顺铂；吉西他滨；非鳞非小细胞肺癌 　　Analysis of the Efficacy of Advanced Non-Small Cell Lung Cancer 　　YAN Ling-li 　　（The First Peoples Hospital of Shuangliu District，Chengdu 610041，Sichuan，China） 　　Abstract：Objective To investigate the efficacy of gemcitabine combined with cisplatin in the first-line treatment of advanced non squamous non-small cell lung cancer.Methods Collected in June～2014 March 2012 in our hospital diagnosed with advanced non-small cell lung cancer patients were randomly divided into 2 groups：50 cases of study group and 50 cases of control group.The study group received treatment with the combination of the United States and the United States，and the control group received gemcitabine plus cisplatin.Comparative study group and the control group average chemotherapy cycle，Results ①Compared with the control group，there was no difference in the average period of chemotherapy and clinical staging（P0.05）.②The efficiency of chemotherapy in the study group and the control group were 36%and 22%，respectively，and the results were quite different（P0.05）.③In the study group and the control group，the platelet reduced and elevated alanine aminotransferase adverse reaction results there was statistically significant difference（P0.05）.Conclusion Pemetrexed/cisplatinthe is good at treating advanced non-small cell lung cancer and the safety. 　　Key words：Pemetrexed；Cisplatin；Gemcitabine；Lung cancer 　　肺癌是世界上发病率和病死率最高的恶性肿瘤之一，其发病率呈逐年增高的趋势，大部分肺癌的病理类型属于非小细胞肺癌[1]。非小细胞肺癌目前的标准治疗仍为含铂两药方案化疗，如紫杉醇、多西他塞、吉西他滨、长春瑞滨。本文探讨了培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的疗效，现报告如下。 　　1 资料与方法 　　1.1一般资料 收集2012年3月～2014年6月我院诊断为晚期非鳞非小细胞肺癌的患者，随机分为两组：50例研究组和50例对照组。研究组接受培美曲塞联